Drug intelligence / Profile preview

brusatol

Development stage
Preclinical
Modality
RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
Administration
Oral (preclinical/traditional Use), Intravenous (preclinical Studies)
01

Overview

Brusatol is a natural quassinoid compound primarily extracted from the seeds of Brucea javanica and Brucea sumatrana, plants used in traditional Chinese medicine[2][4][5]. It is best known as a potent inhibitor of nuclear factor erythroid 2-related factor 2 (Nrf2), a transcription factor that regulates cellular antioxidant responses. By inhibiting Nrf2 signaling, brusatol sensitizes cancer cells to chemotherapeutic agents and promotes apoptosis. Brusatol exhibits broad biological activities including antitumor (notably in colorectal cancer, glioblastoma, pancreatic cancer), antileukemia, anti-inflammatory, antimalarial, antiparasitic (antitrypanosomal), antibacterial and antiviral effects[1][2][3][4][5]. Mechanistically it blocks cell proliferation and cycle progression; induces apoptosis and autophagy; suppresses angiogenesis; inhibits tumor invasion/metastasis; reverses multidrug resistance; inhibits protein synthesis non-selectively[1][3][8]. Recent research also suggests activity against TGF-β signaling via TGFβRII inhibition in some cancers[5], as well as activation of the IL-22/STAT3 pathway for mucosal healing in ulcerative colitis models[5]. Brusatol’s clinical development has been limited by its short-lived effect on Nrf2 and potential toxicity due to non-selective protein synthesis inhibition. Nanoparticle formulations are being explored to improve delivery and reduce toxicity[8].

Other names
brusatolYa-Dan-Zi (Chinese name)quassinoid from Brucea javanica
02

Targets

Beyond the preview

Go deeper on brusatol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on brusatol.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call